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Purpose: Presently there is no published data on the outcomes of localized or locally-advanced prostate cancer (PCa) treated by 
external-beam radiotherapy (RT) in Indonesia.
Methods: This study retrospectively analyzed 96 patients with localized or locally-advanced PCa treated by RT from year 1995 to 
2009, at the national referral hospital and the national cancer hospital of Indonesia. Cumulative prostate and pelvic radiation dose/
type was <70 Gy conventional RT in 84.4% patients, and ≥70 Gy Three dimensional-conformal or intensity modulated RT in 15.6% 
patients. Overall survival (OS) and biochemical progression-free survival (BFS) were estimated by Kaplan-Meier. Predictors of OS and 
biochemical recurrence were analyzed by multivariate Cox regressions. 
Results: The median follow-up was 61 months (range, 24 to 169 months). There were 3.1% low-risk, 26% intermediate-risk, and 70.8% 
high-risk cases. More than half of the patients (52.1%) had pretreatment prostate-specific antigen (PSA) >20 ng/mL. The 5-year survival 
outcome of low-risk, intermediate-risk, and high-risk patients were: OS, 100%, 94.7%, and 67.9% (P=0.297); and BFS, 100%, 94.1%, and 
57.1% (P=0.016), respectively. In the high-risk group, the 5-year OS was 88.3% in patients who received adjuvant hormonal androgen 
deprivation therapy (HT), compared to 53% in RT only, P=0.08. Significant predictors of OS include high-risk group (hazard Ratio [HR], 
9.35; 95% confidence interval [CI], 1.52 to 57.6; P=0.016), adjuvant therapy (HR, 0.175; 95% CI, 0.05 to 0.58; P=0.005), detection by 
transurethral resection of the prostate (TUR-P) (HR, 6.81; 95% CI, 2.28 to 20.33; P=0.001), and pretreatment PSA (HR, 1.003; 95% CI, 1.00 
to 1.005; P=0.039). The sole predictor of biochemical failure was pretreatment PSA (P=0.04), with odds ratio of 4.52 (95% CI, 1.61 to 
12.65) for PSA >20 ng/mL.
Conclusions: RT is an effective treatment modality for localized or locally-advanced PCa in Indonesian patients, with outcomes and 
predictors consistent to that reported elsewhere. Predictors of poorer outcomes include high-risk group, higher pretreatment PSA, 
incidental detection by TUR-P, and lack of adjuvant HT. Adjuvant hormonal therapy significantly improve the survival of high risk 
patients.
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INTRODUCTION
Prostate cancer (PCa) is the second most frequently diag-
nosed cancer of men and the fifth most common cancer 
overall cancer worldwide. Although the incidence is much 
lower in Asia than Western countries, the number has risen 
steadily over the years. Similar trend occurs in Indonesia, cur-
rently with a PCa incidence of 10.3 per 100,000 population, 
which has increased almost threefold in the last decade [1,2]. 
This trend is most likely attributed to the increased availability 
of healthcare access, prostate-specific antigen (PSA) screen-
ing, increased life expectancy and the adoption of Western 
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diet and lifestyle in developing Asian countries [3,4].
 Several treatment options are available for localized PCa, 
including radical prostatectomy (RP), brachytherapy, external 
beam radiation therapy (RT), hormonal androgen depriva-
tion therapy (HT) and active surveillance. The choice of treat-
ment depends on a number of factors including histological 
staging, life expectancy, comorbidities, and the expected 
patient outcomes [5]. 
 Radiotherapy is an effective alternative to surgery for cura-
tive treatment of localized PCa, based on the fact that the long 
term outcomes are similar for both therapies [6,7]. RT is suit-
able for patients who refused or unfit for surgery, those with 
life expectancy of less than 10 years, or high-risk patients as 
determined by higher PSA, Gleason grade, and T stage [8]. 
 More advanced radiation facilities including intensity-
modulated radiation therapy (IMRT) machines are readily 
available for PCa treatment in Indonesia and neighbouring 
countries. However, the number of Asian studies on RT for 
PCa treatment is scarce [9]. This study aims to describe for 
the first time the survival outcome and prognostic factors for 
localized or locally-advanced PCa treated by RT in Indonesia.
MATERIALS AND METHODS
This multi-institutional retrospective study analyzed localized 
or locally-advanced PCa patients who were treated by RT at 
the national referral hospital and the national cancer hospi-
tal of Indonesia. Between years 1995 to 2009, there were 96 
localized or locally-advanced PCa cases treated by RT which 
fulfilled the inclusive criteria of localized (T1 or T2) or locally 
advanced (T3) PCa, with no lymph node or distant metastasis 
(N0, M0). The minimum follow-up period was 2 years.
 The total radiation dose was split into two groups depend-
ing on the type and technique of RT used. The first group 
consisted of patients receiving cumulative dose of less than 70 
Gy, administered by conventional multifield linear accelera-
tor. The second group of patients received total radiation dose 
70 Gy or above using more advanced radiation techniques 
including three dimensional-conformal radiation therapy 
(3D-CRT) and IMRT. Radiations were delivered in a variety of 
fraction sizes, typically 1.8 to 2 Gy for conventional RT, and up 
to 2.5 Gy for IMRT. At the Indonesian national cancer center 
hospital, additional whole pelvic radiations were given to pa-
tients with higher risk of lymphatic spread, as determined by 
the Roach formula of {2/3 PSA+[Gleason score (GS) - 6]×10} 
[10,11]. 
 The primary outcome was overall survival (OS) and bio-
chemical progression-free survival (BFS) for each risk group, 
as well as significant predictors of survival. Additionally, analy-
sis of OS was performed in high-risk patients to evaluate the 
efficacy of adjuvant hormonal therapy. OS was deﬁned from 
the date of diagnosis to mortality of any cause. BFS was de-
termined using the Phoenix definition of biochemical failure 
(BF) of PSA rise by 2 ng/mL above nadir after RT, with or 
without HT [12]. Additional HT was used in selective patients 
in the form of total androgen blockade combining antiandro-
gens with a luteinizing hormone-releasing hormone agonist. 
Neoadjuvant HT was typically given for 3 months prior and/
or concurrent with RT, and adjuvant HT may be given up to 3 
years in high-risk patients. 
 The OS rate and the BFS rate were calculated from the ﬁrst 
day of radiotherapy using the Kaplan-Meier method, with 
pairwise log-rank statistics for comparisons of each risk group. 
Multivariate Cox-regressions were used to identify prognostic 
factors for OS and BFS. Data were analyzed using the SPSS ver. 
16.0 (SPSS Inc., Chicago, IL, USA).
 Adjusted variables in the multivariate models included 
age, detection method by biopsy (10 to 12 cores) or transure-
thral resection of the prostate (TUR-P), radiation dose/type, 
treatment delay, neoadjuvant/adjuvant HT, and D’Amico risk 
groups classified on the basis of pretreatment PSA, GS, and 
clinical T stage. The risk groups were defined as low-risk (T1c-
T2a, GS <7 and PSA ≤10 ng/mL), intermediate-risk (T1b-T2b, 
GS 7, or PSA 11–20 ng/mL) and high-risk (T2c–T3, GS >7, or 
PSA >20 ng/mL) [13].
RESULTS
The median follow-up was 61 months for all patients. The 
median age was 69 years old, range from 50 to 82 years old. 
The patient characteristics are shown in Table 1. The median 
pretreatment PSA was 24.5 ng/mL (range, 1.4 to 732 ng/mL). 
More than half of our patients had PSA >20 ng/mL, and only 
26.2% had initial PSA ≤10 ng/mL. Clinical T stages were 50% 
T1, 34.4% T2, and 15.6% T3 cases. Combined GS groups GS 
2–6, GS 7, and GS 8–10 were 10.4%, 52.1%, and 35.4%, respec-
tively. According to the risk group, there were 3.1% low-risk, 
26% intermediate-risk, and 70.8% high-risk cases. Most of the 
cases were detected by core biopsy (78.1%), and incidental 
findings of PCa by transurethral resection account for 21.9% 
of all cases. 
 The treatment characteristics are summarized in Table 2. 
The median cumulative prostate and pelvic radiation dose in 
our series was 66 Gy (range, 60 to 79 Gy). For subsequent anal-
ysis, radiation dose was grouped into patients who received 
less than 70 Gy using conventional RT (84.4%), and those who 
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received 70 Gy or more using 3D-CRT/IMRT (15.6%). Some of 
the high-risk patients received additional hormonal therapy. 
Neoadjuvant hormonal therapy was used in 33.3% patients, 
adjuvant hormonal therapy in 40.6%, and 17.7% received a 
combination of both. Median delay time to RT was 51.5 days 
(range, 2 to 750 days). BF occurred in 31.2% of all patients.
 Treatment outcomes are summarized in Table 3. The mean 
OS for all patients was 73.6 months, with a 5-year OS rate of 
74.8 % for all patients. The 5-year OS for each risk group was 
100% in low-risk, 94.7% in intermediate-risk, and 67.9% in 
high-risk group (Fig. 1). Pairwise OS log-rank comparisons 
of low- vs. intermediate-risk P=0.374, low- vs. high-risk 
P=0.892, intermediate vs. high-risk P=0.101, overall OS com-
parisons P=0.297. The 5-year BFS for all patients was 68.3%, 
and BFS according to the risk groups were: low-risk, 100%; 
intermediate-risk, 94.1%; and high-risk group, 57.1% (Fig. 2). 
Pairwise BFS log-rank comparisons of low- vs intermediate-
risk P=0.296, low- vs. high-risk P=0.150, intermediate vs. 
Table 1. Patient characteristics
Characteristic Value
Age (yr) 69 (50–82)
Initial PSA (ng/mL) 24.5 (1.4–732)
PSA group (ng/mL)
<4 4 (4.2)
4–10 23 (24)
10.1–20 15 (15.6)
>20 50 (52.1)
Unknown 4 (4.2)
Gleason score group
2–6 10 (10.4)
7 50 (52.1)
8–10 34 (35.4)
Unknown 2 (2.1)
T stage 
T1a 1 (1)
T1b 16 (16.7)
T1c 31 (32.3)
T2a 19 (19.8)
T2b 6 (6.2)
T2c 8 (8.3)
T3 15 (15.6)
Risk group
Low risk 3 (3.1)
Intermediate 25 (26)
High risk 68 (70.8)
Detection method 
Biopsy 75 (78.1)
TUR-P 21 (21.9)
Values are presented as median (range) or number (%).
PSA, prostate-specific antigen; TUR-P, transurethral resection of the 
prostate.
Table 2. Treatment characteristics
Characteristic Value
Radiotherapy dose 66 (60–79)
Radiotherapy dose group
<70 Gy 81 (84.4)
≥70 Gy 15 (15.6)
Hormonal therapy
Neoadjuvant 32 (33.3)
Adjuvant 39 (40.6)
Combination 17 (17.7)
Delay to radiotherapy (day) 51.5 (2–750)
Biochemical failure 30 (31.2)
Values are presented as median (range) or number (%).
Table 3. Treatment outcome
Mean survival 
time (mo)
5-year overall 
survival (%)
Biochemical 
progression- 
free survival (%)
Low-risk 90.0 100 100
Intermediate-risk 82.6 94.7 94.1
High-risk 69.7 67.9 57.1
All patients 73.6 74.8 68.3
Fig. 1. Five-year overall survival. 
Low risk
High risk
Intermediate risk
Cu
m
ul
at
iv
e 
su
rv
iv
al
 (%
)
Time (mo)
100
80
60
40
20
0
 0 10 20 30 40 50 60
Fig. 2. Biochemical progression-free survival.
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kaplan meier, log-rank P=0.297
Biochemical progression-free survival 
kaplan meier, log-rank P=0.016
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high-risk P=0.014, overall BFS comparisons P=0.016. Sub-
analysis of the high-risk group revealed 5-year OS rate of 
88.3% for adjuvant HT group vs. 53% for RT only, P=0.08.
 Independent predictors for OS and BFS are summarized in 
Table 4. Multivariate analysis revealed several significant pre-
dictors of OS, including: high-risk group (compared to inter-
mediate-risk group; hazard ratio [HR], 9.35; 95% confidence 
interval [CI], 1.52 to 57.6; P=0.016), adjuvant HT (compared 
to no adjuvant HT; HR, 0.175; 95% CI, 0.05 to 0.58; P=0.005), 
detection method by TUR-P (compared to detection by pros-
tate biopsy; HR. 6.81; 95% CI, 2.28 to 20.33; P=0.001), and 
higher pre-treatment PSA (HR, 1.003; 95% CI, 1.00 to 1.005; 
P=0.039). The sole predictor of biochemical recurrence was 
pretreatment PSA level (P=0.04), with odds ratio of 4.52 (95% 
CI, 1.61 to 12.65) for PSA >20 ng/mL.
DISCUSSION
Since the introduction of PSA screening, PCa are being de-
tected at earlier stages of disease in Indonesia. Although we 
screened many PCa patients with early localized disease, 
more than 70 percent of our patients were classiﬁed as high-
risk, mainly due to the high initial PSA and Gleason grades. 
Such finding in our patient characteristics is similar to other 
reports stating that Asians have a greater tendency for having 
high-risk disease when matched for stage with the Western 
population [4,14]. More high-risk PCa were treated with RT 
compared to RP in our hospitals, based on the rationale that 
the outcome is similar when patients are matched by stage 
and tumor grade [15]. 
 The 5-year OS and BFS rate were 74.8% and 68.3% in our 
study. For comparison, a compiled report of 34 Japanese in-
stitutions reported a 5-year OS and BFS of 93.0, and 71.9%, 
re spectively [16]. Our survival outcomes were inferior due to 
several reasons. Firstly, we have a higher proportion of high-
risk disease, with over 50% patients presented with initial 
PSA >20 ng/mL, and over 70% cases were high-risk. In Asia, 
advanced stage PCa is known to be more prevalent in devel-
oping countries compared to developed Asian countries such 
as Japan, Singapore, and South Korea [9]. Other contributing 
factors to poorer OS were the lower life expectancy of Indone-
sian males, suboptimal conventional radiation dose admin-
istered in the majority of our patients, and nonuniform use of 
adjuvant hormonal therapy in high-risk cases due to financial 
constraints. 
 The radiation doses employed in our institutions used to 
be lower than those used elsewhere, which explained the 
high rate (31.2%) of BF in our study. More than 80% of our 
patients were treated with a conventional RT, with a median 
radiation dose of 66 Gy. Modern radiotherapy that can de-
liver higher doses, such as IMRT, has only been recently used 
in Indonesia. There is a concern that conventional dose RT 
does not adequately eradicate PCa; long term trial comparing 
conventional RT and high-dose IMRT >72 Gy revealed sig-
nificant decrease of BF from 32.4% to 16.7% [17]. Studies have 
also revealed that radiation dose is a predictor of survival. 
However, similar to that reported in the Japanese study [16], 
radiation dose was not a signiﬁcant survival predictor in our 
analysis.Again, this may be explained by the small proportion 
of patients receiving optimal radiation doses and the nonuni-
form use of adjuvant hormonal therapy for high-risk patients 
in addition to 3D-CRT/IMRT in our centers.
 Several significant predictors of survival were identified in 
the multivariate analysis. Predictors of poorer OS in our series 
were higher pretreatment PSA, high-risk disease, incidental 
detection by TUR-P, and lack of adjuvant HT. Meanwhile for 
biochemical progression, initial PSA level >20 ng/mL was the 
sole predictor of BF in our study. The prognostic factors that 
are used today for localized PCa have not changed during 
recent years; serum PSA has always been identified as one of 
the strongest predictor of survival and biochemical progres-
sion [18]. 
 Studies have shown that long term outcomes of RT for 
treatment of localized or locally-advanced PCa are improved 
when combined with adjuvant hormonal therapy. Long-term 
HT in combination with RT has been shown to be effective in 
high-risk patients [19]. Randomized study in Asian popula-
tion comparing RP and low-dose RT (60 to 70 Gy), both arms 
combined with HT, demonstrated similar survival outcomes 
[6]. Another randomized study also revealed that RP vs. 
Table 4. Multivariate predictors for overall survival and bio-
chemical failure
P-value Hazard 
ratio
Odds 
ratio
95% CI
Overall survival
Detection by TUR-P (vs. 
prostate biopsy)
0.001 6.81 (2.28–20.33)
Adjuvant  therapy (vs. no 
adjuvant)
0.005 0.18 (0.05–0.58)
High-risk group (vs. inter-
mediate-risk)
0.016 9.35 (1.52–57.58)
Initial PSA (continuous 
variable)
0.039 1.003 (1.00–1.005)
Biochemical failure  
Initial PSA>20 ng/mL 0.004 4.52 (1.61–12.66)
CI, confidence interval; TUR-P, transurethral resection of the prostate; 
PSA, prostate-specific antigen.
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RT+HT resulted in similar long-term cancer control for high-
risk PCa [7]. In the present study, adjuvant HT was used in 
40.6% of patients, and was found to significantly increase the 
OS of high-risk group. While adjuvant HT was found to be a 
significant predictor of OS; neither neoadjuvant HT nor treat-
ment delay has any impacts on survival or biochemical recur-
rence. This result is similar to another study which concluded 
that treatment delay to RT has little effect on clinical or bio-
chemical outcome, even in higher risk patients [20]. 
 The clinical significance of incidental PCa detected by 
TUR-P for assumed benign hyperplasia has been a matter of 
debate. The resected tissue originates mainly from the tran-
sition zone of the prostate and tumors from this part of the 
prostate usually have low potential of malignancy [21]. On the 
other hand, up to 37% of all incidental tumours ultimately will 
progress, hence it was suggested that TUR-P detected tumors 
may not exclusively have their origin in the transition zone 
but instead might represent peripheral zone tumors that have 
grown [22]. In the multivariate analysis, detection by TUR-P 
is one of the significant factors associated with poorer out-
come (HR, 6.81; P=0.001). However, this finding may not be 
generalized to all PCa cases because this subgroup of patients 
was heterogeneous. Other factors including age, prostate size, 
PSA, and risk should also be considered. 
 Result from another Asian study revealed additional pre-
dictors for biochemical progression. This includes GS, T stage, 
and whole pelvic radiations [16]. Although GS grading system 
has proven to be a strong prognostic factor for survival [23], 
the clinical T staging is known to be flawed by limitations 
including variability between observers and the inaccuracy 
in determining capsule penetration by digital rectal examina-
tion [24]. Both GS and T stage were not independent variables 
of predictors in our study. However, high-risk disease, which 
incorporated higher Gleason grade >7 and T stage ≥2b, was 
identified as a predictor of survival in our study.
 The effectiveness of elective whole pelvic radiation remains 
a controversy. Vargas et al. [25] concluded a lack of benefit 
of pelvic radiation in PCa with a high risk of positive pelvic 
lymph nodes treated with high-dose radiation. On the other 
hand, recent randomized study has shown improvement of 
progression-free survival when additional pelvic radiation 
was used in conjunction with neoadjuvant or concurrent HT 
in high risk PCa [10].
 Acute side effects of radiotherapy may occur up to 3 months 
post radiation, typically proctitis, diarrhea, rectal bleeding, 
radiation cystitis, and hematuria. Some of the more severe 
long-term complications of RT may include urethral stricture, 
incontinence, and erectile dysfunction. Patients who received 
high-dose IMRT did not suffer more complications, as it al-
lowed safe escalation of radiation dose with low toxicity [26]. 
Perhaps because most of our patients received radiation 
doses lower than 70 Gy, the side effects were generally mild 
and well tolerated. So far, there were only less than 2% of all 
patients who suffered prolonged bladder irritation or enteri-
tis. To prevent gastrointestinal morbidities, at the Indonesian 
national cancer center hospital, patients were radiated in a 
prone position to exclude the bowels from radiation field [11].
 The limitations of this study include all those inherent in 
a retrospective analysis. Although all data elements were 
prospectively collected and follow-up were done periodi-
cally, there were a lot of lost cases excluded from analysis. The 
remaining sample eligible for analysis may result in overes-
timation or underestimation of survival. Moreover, cause of 
mortality ascertainment is likely to be inaccurate with passive 
follow-up, thus we were unable to analyze the disease-specif-
ic survival of our patients. 
 The number of patients was considered too small for ac-
curate analysis of predictive factors. Androgen blockage is 
considered significant factor after RT in localized and locally 
advanced PCa. However, neo- or adjuvant therapy schedule 
lacks consistency in our series.
 In conclusion, this multi-institution study describes for the 
first time the survival and predictors of localized or locally-
advanced PCa treated by RT in Indonesia. Despite the fact 
that the majority of our patients received suboptimal radia-
tion dose, radiotherapy remains an effective treatment mo-
dality for localized or locally-advanced PCa in Indonesian 
patients, with outcomes and predictors consistent to that 
reported elsewhere. 
 Predictors of poorer outcomes in our series were high-risk 
disease, higher pretreatment PSA, incidental detection by 
TUR-P, and lack of adjuvant HT. Adjuvant hormonal therapy 
has been shown to significantly improve survival outcomes 
in high risk cases, thus warranting its routine use in this select 
group of patients. 
 In recent years, RT has become one of the preferred treat-
ment options for localized or locally-advanced PCa in Indo-
nesia. We believe future studies on radiotherapy for PCa in 
Indonesia would show promising results as advanced radio-
therapy tecniques including IMRT become readily available 
in more Indonesian hospitals.
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